In a major regulatory intervention aimed at eliminating market profiteering and expanding healthcare affordability, the National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has mandated sharp price reductions across critical lifesaving medicines. The directive enforces reductions of up to 70% on the Maximum Retail Price (MRP) of selected essential drug formulations.
The decisive price rationalization is projected to deliver an estimated ₹2,500 crore in annual out-of-pocket savings for patients and families across India. By capping trade margins and enforcing strict ceiling prices under the Drugs (Prices Control) Order (DPCO), the pricing authority seeks to curb unreasonable trade markups, ensure uninterrupted domestic availability, and prioritize public health over excessive commercial margins.
The initiative aligns with the Government of India’s broader mandate to make essential and high-cost clinical therapies universally accessible. State Drug Controllers and enforcement authorities have been tasked with monitoring retail channels, hospital pharmacies, and distribution networks to ensure manufacturers and retailers immediately pass on the revised MRP caps to consumers without supply chain disruption.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
